Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: budesonide
Trade Name: Eohilia
Date Designated: 12/20/2006
Orphan Designation: Treatment of patients with eosinophilic esophagitis
Orphan Designation Status: Designated/Approved
Takeda Pharmaceuticals U.S.A., Inc.
500 Kendall Street
Cambridge, Massachusetts 02142
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: budesonide
Trade Name: Eohilia
Marketing Approval Date: 02/09/2024
Approved Labeled Indication: treatment for 12 weeks in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE)
Exclusivity End Date: 02/09/2031 
Exclusivity Protected Indication* :  treatment of adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE)
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-